Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hypertension Rx Labels Should Include Product-Specific CV Data – Cmte.

Executive Summary

Data on antihypertensives that have shown cardiovascular endpoint benefits in well-controlled trials should be included in labeling, FDA and the Cardiovascular & Renal Drugs Advisory Committee agreed at a June 15 meeting

You may also be interested in...



Hypertension Labeling Should Say Classes Are All Effective, But Unequally So

Antihypertensive drug class labeling for cardiovascular outcomes should specify that some classes of agents are more effective at reducing such events than others, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said

Hypertension Labeling Should Say Classes Are All Effective, But Unequally So

Antihypertensive drug class labeling for cardiovascular outcomes should specify that some classes of agents are more effective at reducing such events than others, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said

Drug Safety Stays At Top Of FDA’s Agenda With New Guidances In The Works

Drug safety will remain a primary focus of FDA's guidance development efforts, according to the Center for Drug Evaluation & Research's 2006 guidance agenda

Related Content

Topics

UsernamePublicRestriction

Register

PS045959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel